Allergy and asthma medical group services provide specialist, multidisciplinary care for patients living with allergic conditions and respiratory disorders. Whether you are seeking care through an NHS allergy clinic in the UK or exploring what a dedicated allergy and asthma medical group offers, understanding the scope of these services is essential. From diagnosing complex food allergies and anaphylaxis to managing severe, difficult-to-control asthma with biologic therapies, specialist allergy and asthma services go well beyond what a GP can offer in a standard consultation. This guide explains what these services do, the conditions they treat, and when to seek specialist advice.

What Is an Allergy and Asthma Medical Group?

An allergy and asthma medical group is a specialist clinical service dedicated to the diagnosis, management, and ongoing care of patients living with allergic conditions and respiratory disorders such as asthma. These groups typically bring together specialist physicians, specialist nurses, and allied health professionals to provide a multidisciplinary approach to care.

Have any more questions about this? Message our pharmaceutical team to get more info →

In the UK, equivalent services are delivered through NHS allergy clinics, clinical immunology departments, respiratory outpatient services, and — in some cases — dermatology or ENT services with an allergy focus. It is worth noting that NHS specialist allergy provision varies considerably across regions; not all areas have a dedicated allergy service, and patients may be seen within clinical immunology, respiratory medicine, or other specialty settings depending on local commissioning arrangements. UK care follows pathways set by NICE, the MHRA, and local NHS Integrated Care Board (ICB) or Integrated Care System (ICS) guidelines.

The primary aim of such a service is to offer evidence-based, patient-centred care that goes beyond what a general practitioner (GP) can provide in a standard consultation. Patients referred to these services often have complex, poorly controlled, or difficult-to-diagnose conditions that require specialist investigation and tailored treatment plans.

In the context of a location such as Pleasanton in the United States, allergy and asthma medical groups function similarly to UK specialist allergy services in their clinical aims. There is no formal affiliation between any specific overseas medical group and NHS services. Whilst the healthcare systems differ, the underlying clinical principles of allergy and asthma care remain broadly consistent across well-regulated healthcare systems. Understanding what these specialist services offer can help patients in any setting advocate for appropriate referral and care.

Common Allergies and Asthma Conditions Treated

Allergy and asthma specialist services manage a wide spectrum of conditions. The most frequently encountered include:

• Allergic rhinitis (hay fever): inflammation of the nasal passages triggered by allergens such as pollen, house dust mites, or pet dander

• Asthma: a chronic inflammatory airway condition characterised by reversible airflow obstruction, wheeze, breathlessness, and cough

• Food allergies: including reactions to peanuts, tree nuts, milk, eggs, wheat, and shellfish

• Drug allergies: such as reactions to penicillin or non-steroidal anti-inflammatory drugs (NSAIDs); assessment and referral are guided by NICE CG183

• Eczema (atopic dermatitis): a chronic inflammatory skin condition frequently associated with other atopic diseases

• Urticaria and angioedema: hives and deeper tissue swelling, which may be allergic or non-allergic in origin

• Anaphylaxis: a severe, potentially life-threatening systemic allergic reaction

• Chronic rhinosinusitis (with or without nasal polyps): a common coexisting airway condition in people with asthma or atopy

Many patients present with atopic comorbidities — for example, a child with eczema who later develops food allergy and asthma, a pattern known as the "atopic march." Recognising these overlapping conditions is essential, as managing one effectively can positively influence the others.

Asthma alone affects approximately 5.4 million people in the UK, according to Asthma + Lung UK. NICE guideline NG80 emphasises the importance of accurate diagnosis to avoid both under- and over-treatment. Specialist services are particularly well placed to distinguish asthma from other causes of breathlessness, such as vocal cord dysfunction or cardiac conditions, ensuring patients receive the most appropriate care.

Diagnosis and Assessment for Allergy and Asthma

Accurate diagnosis is the cornerstone of effective allergy and asthma management. A specialist assessment typically begins with a thorough clinical history, exploring symptom patterns, triggers, family history of atopy, occupational exposures, and the impact of symptoms on daily life. This detailed history often provides more diagnostic clarity than any single test.

Have any more questions about this? Message our pharmaceutical team to get more info →

For asthma, NICE guideline NG80 recommends objective testing to confirm the diagnosis. Key investigations include:

• Spirometry with bronchodilator reversibility testing: measures airflow limitation and its reversibility

• FeNO (fractional exhaled nitric oxide) testing: a non-invasive marker of eosinophilic airway inflammation; a value of ≥40 ppb in adults is considered a positive result in the context of NICE NG80

• Peak expiratory flow (PEF) variability: recorded over two to four weeks; variability of more than 20% supports a diagnosis of asthma

• Bronchial challenge testing: used in cases where the diagnosis remains uncertain after initial investigations

For allergic conditions, investigations may include:

• Skin prick testing (SPT): a rapid, reliable method for identifying IgE-mediated sensitisation to common allergens, performed in accordance with BSACI guidance

• Specific IgE blood tests: useful when SPT is not feasible — for example, in patients with extensive eczema or those unable to stop antihistamines; results are reported in kU/L and interpreted alongside clinical history

• Oral food challenges: conducted under specialist supervision in a hospital or day-case setting with full resuscitation facilities available, to confirm or exclude food allergy

• Component-resolved diagnostics (CRD): advanced blood testing to assess the risk profile of specific allergen sensitisations; this is a specialist-led investigation, not routinely required, and its use is guided by clinical context and local availability

It is important to note that a positive allergy test indicates sensitisation, not necessarily clinical allergy. Results must always be interpreted alongside the patient's history. Specialist services are trained to integrate these findings to reach a clinically meaningful diagnosis and avoid unnecessary dietary restrictions or overmedication.

Treatment Options and Medicines Used

Treatment for allergy and asthma is highly individualised, guided by diagnosis, severity, patient preference, and comorbidities. Both conditions are managed using a stepwise approach in line with NICE guideline NG80 and SIGN 158 (the British guideline on the management of asthma).

For asthma, the principal medicines include:

• Short-acting beta-2 agonists (SABAs) such as salbutamol: used as reliever inhalers for acute symptom relief; frequent use (more than three times per week) indicates poor control and should prompt review

• Inhaled corticosteroids (ICS) such as beclometasone or fluticasone: the mainstay of preventer therapy, reducing airway inflammation

• ICS–formoterol maintenance and reliever therapy (MART): a NICE-recommended regimen in which a single ICS–formoterol inhaler is used for both daily maintenance and as-needed relief, helping to reduce reliance on SABAs

• Long-acting beta-2 agonists (LABAs) such as salmeterol or formoterol: used in combination with ICS for patients with inadequately controlled asthma; LABAs must not be used without an ICS

• Long-acting muscarinic antagonists (LAMAs) such as tiotropium: an add-on option for selected patients whose asthma remains poorly controlled on ICS–LABA therapy

• Leukotriene receptor antagonists (LTRAs) such as montelukast: an add-on oral therapy with anti-inflammatory properties. Important safety note: the MHRA issued a Drug Safety Update in 2019 advising that montelukast can cause neuropsychiatric reactions (including sleep disturbances, mood changes, and suicidal thoughts). Patients and carers should be counselled about these risks before starting treatment and advised to seek medical review if such symptoms occur. Suspected adverse reactions should be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk)

• Biologic therapies: NICE has approved several biologic medicines for severe, refractory asthma in defined patient populations, including omalizumab (anti-IgE), mepolizumab and reslizumab (anti-IL-5), benralizumab (anti-IL-5 receptor), dupilumab (anti-IL-4/IL-13), and tezepelumab (anti-TSLP). Eligibility criteria are set out in the relevant NICE Technology Appraisals and these treatments are initiated and monitored in specialist severe asthma services

For allergic conditions, treatment options include:

• Non-sedating antihistamines (e.g., cetirizine, loratadine): first-line for allergic rhinitis and urticaria

• Intranasal corticosteroids (e.g., fluticasone nasal spray): highly effective for allergic rhinitis

• Adrenaline auto-injectors (AAIs): prescribed for patients at risk of anaphylaxis. UK-available devices include EpiPen and Jext. In line with MHRA safety advice, patients should carry two in-date devices at all times, receive training in their use, and ensure that carers and close contacts are also trained. After using an AAI, patients must call 999 and attend an emergency department for observation, even if symptoms appear to improve

• Allergen immunotherapy (AIT): subcutaneous or sublingual desensitisation, offering the potential for long-term disease modification in selected patients with allergic rhinitis or venom allergy, delivered in accordance with BSACI guidance

All medicines should be prescribed and monitored in accordance with MHRA guidance and the current British National Formulary (BNF). Inhaler technique and adherence should be reviewed at every clinical encounter, as poor technique is a leading cause of suboptimal asthma control.

Managing Allergy and Asthma Long Term

Long-term management of allergy and asthma requires a proactive, structured approach that empowers patients to understand and control their conditions. Self-management education is a central component of NICE-recommended care (NICE QS25) and has been shown to reduce emergency attendances and improve quality of life.

Key elements of long-term management include:

• Written asthma action plans: personalised documents that guide patients on adjusting treatment in response to worsening symptoms or peak flow readings; templates are available from Asthma + Lung UK and NHS resources

• Regular review appointments: at least annually in primary care, or more frequently for those with moderate-to-severe disease; each review should include checks of inhaler technique, adherence, and symptom control

• Trigger identification and avoidance: common triggers include house dust mites, pet allergens, tobacco smoke, cold air, exercise, and occupational exposures

• Allergen avoidance strategies: for food-allergic patients, this includes careful label reading, carrying emergency medication, and educating carers and schools

• Vaccination: many people with asthma are eligible for the annual influenza vaccine and other NHS-recommended vaccinations; patients should discuss their eligibility with their GP

• Smoking cessation support: smoking significantly worsens both asthma control and allergic inflammation; NHS Stop Smoking Services offer evidence-based support

• Weight management and physical activity: maintaining a healthy weight and remaining physically active can support better asthma control; advice should be tailored to the individual

For patients with severe or difficult-to-control asthma, referral to a specialist severe asthma service is recommended. These services can assess for alternative diagnoses, optimise adherence, and consider eligibility for biologic therapies.

Mental health should not be overlooked. Anxiety and depression are more prevalent in people with chronic respiratory and allergic conditions, and psychological support may form part of a holistic management plan. Patients are encouraged to engage with patient organisations such as Asthma + Lung UK and Allergy UK, which provide reliable, evidence-based resources and peer support networks.

When to Seek Specialist Medical Advice

Knowing when to escalate care is an essential aspect of safe allergy and asthma management. Whilst many patients are well managed in primary care, certain clinical situations warrant prompt referral to a specialist allergy and asthma service.

Contact your GP or seek urgent medical attention if you experience:

• A sudden or severe worsening of asthma symptoms that does not respond to your reliever inhaler

• Breathlessness at rest, difficulty completing sentences, or a blue tinge to the lips (cyanosis) — these are signs of a severe or life-threatening asthma attack requiring emergency care (call 999). A peak expiratory flow (PEF) of less than 50% of your personal best or predicted value indicates a severe attack

• A suspected anaphylactic reaction: symptoms include throat tightening, widespread urticaria, dizziness, vomiting, and collapse — use your adrenaline auto-injector, call 999 immediately, and attend an emergency department for observation even if symptoms improve after using the device

• Frequent use of your reliever inhaler (more than three times per week), which suggests poor asthma control

• A new or unexplained allergic reaction, particularly if severe or recurrent

Referral to a specialist is recommended when:

• The diagnosis of asthma or allergy is uncertain

• Symptoms remain poorly controlled despite appropriate first- and second-line treatment

• A patient requires allergen immunotherapy

• There is a history of anaphylaxis or high-risk food allergy requiring formal assessment (in line with NICE NG213)

• Occupational asthma or allergy is suspected

In the UK, GP referrals to NHS allergy or respiratory services follow NICE guidance and local NHS ICB or ICS referral pathways. Patients should not hesitate to discuss their concerns with their GP, as early specialist input can prevent deterioration and significantly improve long-term outcomes. There is no official link between any specific overseas medical group and NHS services, but the clinical principles guiding specialist allergy and asthma care remain consistent across well-regulated healthcare systems.

Frequently Asked Questions